Problem to solve:
Uveal ocular melanoma is the most common primary ocular malignancy in adults, with an incidence of approximately 7 cases per million inhabitants per year. Its incidence is therefore not very high, but it is a disease for which there are has been no alternative for more than 50 years. In addition, the American Cancer Society has published an increase in the incidence, having been diagnosed only in the United States 2,730 new cases in 2014. By the year 2018 there are anticipated 3,540 new cases in the USA.
According to www.cancer.gov, the database of the National Cancer Institute of the USA, the age-adjusted average incidence of uveal melanoma in the United States is about 4.3 new cases per million inhabitants, without a clear variation related to latitude. Men have a higher incidence than women (4.9 vs. 3.7 per million). The age-adjusted incidence of this cancer has remained stable since at least the first years of the 1970s. Incidence rates in the United States are low compared with the rates of other reporting countries, which range from 5.3 to 10.9 cases per million. Part of the variation may be the result of differences in the inclusion criteria and calculation methods.
Innovation:
The present invention provides an in vitro method for detecting tumor growth and diagnosing or prognosticating the risk of metastasis in a human subject that has been diagnosed with uveal melanoma, wherein the biological sample is treated with a lysis agent capable of disrupting the membrane of the exosomes prior to determining the expression of the melanocyte protein PMEL/ME20-S/gp 100.
This method incorporates new techniques that differentiate it from the potential competitors in several
aspects. Our method is non-invasive (as it does not require a tumor biopsy), it does not require specific training and
sampling is included in the hospital routine (blood extraction). Besides, it can be used after the application of the treatment,
allowing not only to monitor the tumor advance and the early development of metastasis but also to help monitoring the
effect of the treatment. In addition, it would be a more economical method.
Current development status
Experimental technologies
Analytical validation already performed
Applications
Prognosis
Treatment monitoring
Desired business relationship
Patent licensing
Technology co-development
The Health Research Institute of Santiago de Compostela Foundation (FIDIS) is a non-profit institution that promotes translational research, innovation and teaching in the clinical area of the health areas of Santiago de Compostela, Lugo, Cervo and Monforte.
We are the biggest health research institution in the northwest of Spain supporting more than 1000 researchers integrated in 80 research groups and organised in 6 scientific áreas:
-Oncology
-Genetics and Systems Biology
-Endocrinology
-Neuroscience
-Platform and Methodology
-Inflammation
To achieve this, we use innovation as a tool to transfer the results of research to society. In this process of translating knowledge, a key role is played by the business fabric of different areas: technological, food, pharmaceutical, with which FIDIS maintains close and permanent collaborations.
Our goal is to be a reference in specialized management and the promotion of research in the healthcare environment. We act as support for the research groups in all phases of the value chain of biomedical research in particular, and in the area of health in general.
The main objective is to transfer the new scientific knowledge in biomedicine to the society.
Create your free account to connect with Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS) and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS)
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
